153 related articles for article (PubMed ID: 31156375)
1. Embelin, a Potent Molecule for Alzheimer's Disease: A Proof of Concept From Blood-Brain Barrier Permeability, Acetylcholinesterase Inhibition and Molecular Docking Studies.
Bhuvanendran S; Hanapi NA; Ahemad N; Othman I; Yusof SR; Shaikh MF
Front Neurosci; 2019; 13():495. PubMed ID: 31156375
[TBL] [Abstract][Full Text] [Related]
2. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
[TBL] [Abstract][Full Text] [Related]
3. Identification of embelin, a 3-undecyl-1,4-benzoquinone from Embelia ribes as a multitargeted anti-Alzheimer agent.
Nuthakki VK; Sharma A; Kumar A; Bharate SB
Drug Dev Res; 2019 Aug; 80(5):655-665. PubMed ID: 31050027
[TBL] [Abstract][Full Text] [Related]
4. Docking-based design and synthesis of galantamine-camphane hybrids as inhibitors of acetylcholinesterase.
Stavrakov G; Philipova I; Zheleva-Dimitrova D; Valkova I; Salamanova E; Konstantinov S; Doytchinova I
Chem Biol Drug Des; 2017 Nov; 90(5):709-718. PubMed ID: 28374576
[TBL] [Abstract][Full Text] [Related]
5. Luteolin Inhibits Fibrillary β-Amyloid
Zhang JX; Xing JG; Wang LL; Jiang HL; Guo SL; Liu R
Molecules; 2017 Feb; 22(3):. PubMed ID: 28245546
[TBL] [Abstract][Full Text] [Related]
6.
Rupesh R; Mohankumar R; Sabarathinam S
Nat Prod Res; 2023 Sep; ():1-5. PubMed ID: 37690004
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models.
Hu HH; Bian YC; Liu Y; Sheng R; Jiang HD; Yu LS; Hu YZ; Zeng S
Int J Pharm; 2014 Jan; 460(1-2):101-7. PubMed ID: 24262988
[TBL] [Abstract][Full Text] [Related]
8. Primary Porcine Brain Endothelial Cells as In Vitro Model to Study Effects of Ultrasound and Microbubbles on Blood-Brain Barrier Function.
Lelu S; Afadzi M; Berg S; Aslund AK; Torp SH; Sattler W; de L Davies C
IEEE Trans Ultrason Ferroelectr Freq Control; 2017 Jan; 64(1):281-290. PubMed ID: 27529871
[TBL] [Abstract][Full Text] [Related]
9. Improved Method for the Establishment of an In Vitro Blood-Brain Barrier Model Based on Porcine Brain Endothelial Cells.
Nielsen SSE; Siupka P; Georgian A; Preston JE; Tóth AE; Yusof SR; Abbott NJ; Nielsen MS
J Vis Exp; 2017 Sep; (127):. PubMed ID: 28994773
[TBL] [Abstract][Full Text] [Related]
10. Blood-brain barrier permeable anticholinesterase aurones: synthesis, structure-activity relationship, and drug-like properties.
Liew KF; Chan KL; Lee CY
Eur J Med Chem; 2015 Apr; 94():195-210. PubMed ID: 25768702
[TBL] [Abstract][Full Text] [Related]
11. Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier.
Kuntz M; Candela P; Saint-Pol J; Lamartinière Y; Boucau MC; Sevin E; Fenart L; Gosselet F
J Alzheimers Dis; 2015; 48(3):849-62. PubMed ID: 26402114
[TBL] [Abstract][Full Text] [Related]
12. Effect on Acetylcholinesterase and Anti-oxidant Activity of Synthetic Chalcones having a Good Predicted Pharmacokinetic Profile.
Sakata RP; Figueiro M; Kawano DF; Almeida WP
Med Chem; 2017; 13(7):654-663. PubMed ID: 28545385
[TBL] [Abstract][Full Text] [Related]
13. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
14. In vitro porcine blood-brain barrier model for permeability studies: pCEL-X software pKa(FLUX) method for aqueous boundary layer correction and detailed data analysis.
Yusof SR; Avdeef A; Abbott NJ
Eur J Pharm Sci; 2014 Dec; 65():98-111. PubMed ID: 25239510
[TBL] [Abstract][Full Text] [Related]
15. Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier.
Biemans EALM; Jäkel L; de Waal RMW; Kuiperij HB; Verbeek MM
J Neurosci Res; 2017 Jul; 95(7):1513-1522. PubMed ID: 27726164
[TBL] [Abstract][Full Text] [Related]
16. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
17. Development of the "hidden" multifunctional agents for Alzheimer's disease.
Huang W; Liang M; Li Q; Zheng X; Zhang C; Wang Q; Tang L; Zhang Z; Wang B; Shen Z
Eur J Med Chem; 2019 Sep; 177():247-258. PubMed ID: 31158742
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Angiogenesis and Nitric Oxide Synthase (NOS), by Embelin & Vilangin Using in vitro, in vivo & in Silico Studies.
Narayanaswamy R; Shymatak M; Chatterjee S; Wai LK; Arumugam G
Adv Pharm Bull; 2014 Dec; 4(Suppl 2):543-8. PubMed ID: 25671187
[TBL] [Abstract][Full Text] [Related]
19. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma.
Poduslo JF; Curran GL; Kumar A; Frangione B; Soto C
J Neurobiol; 1999 Jun; 39(3):371-82. PubMed ID: 10363910
[TBL] [Abstract][Full Text] [Related]
20. Identification of Human Acetylcholinesterase Inhibitors from the Constituents of EGb761 by Modeling Docking and Molecular Dynamics Simulations.
Zhang L; Li D; Cao F; Xiao W; Zhao L; Ding G; Wang ZZ
Comb Chem High Throughput Screen; 2018; 21(1):41-49. PubMed ID: 29173156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
